Sweet cherry is non-climacteric: it does not ripen on ethylene alone, so blocking ethylene perception — the sole action of 1-MCP — does little to arrest deterioration. Post-harvest quality loss in cherry is driven instead by a parallel cascade of hydrolytic and oxidative enzymes that soften the flesh, brown the skin and pedicel, and break down cell membranes. Hi Cell Renova is a botanical treatment that inhibits eight of these pathways at once — which is why, in trial, it outperformed both an untreated control and 1-MCP
Why cherry needs a different approach
Single-target chemistry cannot hold cherry. 1-MCP blocks only ethylene perception; surface coatings only slow gas and moisture exchange. Neither touches the PME–PG–cellulase softening axis or the PPO-driven browning that actually degrade the fruit. Renova works with the fruit’s own biology — not as a surface film — addressing the underlying science of senescence directly.
The enzyme pathways Renova targets
Each pathway below contributes to a specific mode of cherry deterioration. Renova inhibits all eight simultaneously, preserving firmness, colour, and membrane integrity together rather than any one in isolation.
Why acting on every pathway at once matters
Firmness, colour and flavour are lost through different enzymes on different timelines. A treatment that addresses only one leaves the others free to run. By acting across the whole cascade, Renova removes the compensating pathways that let fruit soften and brown even when a single process is blocked — the mechanistic reason it holds cherry where narrower technologies fail.
Proven in trial
Trial CH011/FD/US/5/26 — a completely randomised design across five treatments (Control, 1-MCP, and Renova at three doses) on Bling variety sweet cherry, held at a deliberately sub-optimal 3–5 °C for 20 days. Sub-optimal conditions make this a conservative test: efficacy on premium varieties under optimal cold chain is expected to be stronger.
The bottom line. Because cherry deterioration is enzymatic and oxidative rather than ethylene-led, only a multi-pathway treatment can hold it. In trial, Renova cut the senescence rate by roughly 42% and completely arrested average firmness loss under sub-optimal storage — while 1-MCP was statistically indistinguishable from doing nothing. That is direct evidence Renova acts where single-target technologies cannot